NVO Rallies 11% in a Month: How Should Investors Play the Stock?

Novo Nordisk shares are up ~11% over the past month as access to Wegovy expands and a U.K. approval lifts optimism for GLP-1 demand. However, management faces earnings pressure as competition increases, clouding the near-term outlook despite the positive approvals.

Analysis

Novo Nordisk shares are up ~11% over the past month as access to Wegovy expands and a U.K. approval lifts optimism for GLP-1 demand. However, management faces earnings pressure as competition increases, clouding the near-term outlook despite the positive approvals.